Aarash Saleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aarash Saleh has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Bessie Kwok
Centre for Inflammation and Tissue Repair, UCL Respiratory Medicine, Royal Free Campus, University College London, London, UK
2 shared publicationsH. Raichura
2 shared publicationsH. Wilkinson
2 shared publicationsJ. Emmanuel
2 shared publicationsJ. Hurst
UCL Respiratory, University College London
2 shared publicationsJohn R. Hurst
Centre for Inflammation and Tissue Repair, UCL Respiratory Medicine, Royal Free Campus, University College London, London, UK
2 shared publications
Latest Publications
- Open Access
The local and systemic response to SARS-CoV-2 infection in children and adults
While a substantial proportion of adults infected with SARS-CoV-2 progress to develop severe disease, children rarely manifest respiratory complications. Therefore, understanding differences in the local and systemic response to SARS-CoV-2 infection between children and adults may provide important clues about the pathogenesis of SARS-CoV-2 infection. To address this, we first generated a healthy reference multi-omics single cell data set from children (n=30) in whom we have profiled triple matched samples: nasal and tracheal brushings and PBMCs, where we track the developmental changes for 42 airway and 31 blood cell populations from infancy, through childhood to adolescence. This has revealed the presence of naive B and T lymphocytes in neonates and infants with a unique gene expression signature bearing hallmarks of innate immunity. We then contrast the healthy reference with equivalent data from severe paediatric and adult COVID-19 patients (total n=27), from the same three types of samples: upper and lower airways and blood. We found striking differences: children with COVID-19 as opposed to adults had a higher proportion of innate lymphoid and non-clonally expanded naive T cells in peripheral blood, and a limited interferon-response signature. In the airway epithelium, we found the highest viral load in goblet and ciliated cells and describe a novel inflammatory epithelial cell population. These cells represent a transitional regenerative state between secretory and ciliated cells; they were found in healthy children and were enriched in paediatric and adult COVID-19 patients. Epithelial cells display an antiviral and neutrophil-recruiting gene signature that is weaker in severe paediatric versus adult COVID-19. Our matched blood and airway samples allowed us to study the spatial dynamics of infection. Lastly, we provide a user-friendly interface for this data 1 as a highly granular reference for the study of immune responses in airways and blood in children.
Open AccessThe local and systemic response to SARS-CoV-2 infection in children and adults
While a substantial proportion of adults infected with SARS-CoV-2 progress to develop severe disease, children rarely manifest respiratory complications. Therefore, understanding differences in the local and systemic response to SARS-CoV-2 infection between children and adults may provide important clues about the pathogenesis of SARS-CoV-2 infection. To address this, we first generated a healthy reference multi-omics single cell data set from children (n=30) in whom we have profiled triple matched samples: nasal and tracheal brushings and PBMCs, where we track the developmental changes for 42 airway and 31 blood cell populations from infancy, through childhood to adolescence. This has revealed the presence of naive B and T lymphocytes in neonates and infants with a unique gene expression signature bearing hallmarks of innate immunity. We then contrast the healthy reference with equivalent data from severe paediatric and adult COVID-19 patients (total n=27), from the same three types of samples: upper and lower airways and blood. We found striking differences: children with COVID-19 as opposed to adults had a higher proportion of innate lymphoid and non-clonally expanded naive T cells in peripheral blood, and a limited interferon-response signature. In the airway epithelium, we found the highest viral load in goblet and ciliated cells and describe a novel inflammatory epithelial cell population. These cells represent a transitional regenerative state between secretory and ciliated cells; they were found in healthy children and were enriched in paediatric and adult COVID-19 patients. Epithelial cells display an antiviral and neutrophil-recruiting gene signature that is weaker in severe paediatric versus adult COVID-19. Our matched blood and airway samples allowed us to study the spatial dynamics of infection. Lastly, we provide a user-friendly interface for this data 1 as a highly granular reference for the study of immune responses in airways and blood in children.
- 22 November 2017
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (5) , 1701127
Correlates and assessment of excess cardiovascular risk in bronchiectasis
Patients with bronchiectasis are at increased risk of cardiovascular disease. We aimed to identify factors associated with elevated cardiovascular risk in bronchiectasis, measured using aortic stiffness and cardiac biomarkers. In addition, we sought to compare these direct measures against calculated QRISK2 scores.Aortic stiffness, cardiac biomarkers and systemic inflammation were measured in 101 adults with stable bronchiectasis. In addition, clinical and demographic data were collected to allow calculation of QRISK2 score and the bronchiectasis severity index (BSI) for each patient.The BSI score correlated with measured cardiovascular risk assessments, partly due to greater exacerbation frequency and lower forced expiratory volume in 1 s. Pulse-wave velocity was significantly higher in frequent exacerbators (≥3 events·year-1) than infrequent exacerbators (-1; 10.5versus9.2 m·s−1, p=0.01). In addition, frequent exacerbators had elevated serum C-reactive protein concentration, suggesting increased systemic inflammation (4.8versus2.2 mg·L−1, p=0.005). QRISK2 systematically underestimated cardiovascular risk in this population (median change in relative risk 1.29). Underestimation was associated with frequent exacerbations and male sex.Patients with bronchiectasis have greater cardiovascular risk than published reference populations. Excess cardiovascular risk is associated with exacerbation frequency and impaired lung function. Cardiovascular risk assessment in bronchiectasis should be individualised, as calculation tools are likely to underestimate the risk in this population.
- 22 November 2017
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (5) , 1701127
Correlates and assessment of excess cardiovascular risk in bronchiectasis
Patients with bronchiectasis are at increased risk of cardiovascular disease. We aimed to identify factors associated with elevated cardiovascular risk in bronchiectasis, measured using aortic stiffness and cardiac biomarkers. In addition, we sought to compare these direct measures against calculated QRISK2 scores.Aortic stiffness, cardiac biomarkers and systemic inflammation were measured in 101 adults with stable bronchiectasis. In addition, clinical and demographic data were collected to allow calculation of QRISK2 score and the bronchiectasis severity index (BSI) for each patient.The BSI score correlated with measured cardiovascular risk assessments, partly due to greater exacerbation frequency and lower forced expiratory volume in 1 s. Pulse-wave velocity was significantly higher in frequent exacerbators (≥3 events·year-1) than infrequent exacerbators (-1; 10.5versus9.2 m·s−1, p=0.01). In addition, frequent exacerbators had elevated serum C-reactive protein concentration, suggesting increased systemic inflammation (4.8versus2.2 mg·L−1, p=0.005). QRISK2 systematically underestimated cardiovascular risk in this population (median change in relative risk 1.29). Underestimation was associated with frequent exacerbations and male sex.Patients with bronchiectasis have greater cardiovascular risk than published reference populations. Excess cardiovascular risk is associated with exacerbation frequency and impaired lung function. Cardiovascular risk assessment in bronchiectasis should be individualised, as calculation tools are likely to underestimate the risk in this population.
- Open Access
- 29 November 2016
- Published by SAGE Publications in Journal of the Intensive Care Society
- Vol. 18 (2) , 138-142
A case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration
We present the case of an 88-year-old gentleman who presented to hospital septic with bilateral leg cellulitis, pulmonary oedema and hypotension. He had no history of heart disease but had had bilateral carpal tunnel releases. His condition deteriorated with refractory hypotension in spite of fluid filling, inotropic and vasopressor support. His echocardiogram showed an infiltrative cardiomyopathy with a speckled myocardium, severe concentric left and right ventricular increased wall thickness, diastolic dysfunction, biatrial dilatation and restrictive physiology in keeping with cardiac amyloidosis. He developed atrial fibrillation and worsening respiratory failure due to fluid overload and was intubated and ventilated but continued to decline and passed away. The degree of heart failure in the absence of ischaemia, the patient’s advanced age, echocardiographic findings and past history of carpal tunnel syndrome in a male are strongly indicative of a diagnosis of wild-type cardiac transthyretin amyloidosis. We discuss the key features and intensive care management of this disease.
- 29 November 2016
- Published by SAGE Publications in Journal of the Intensive Care Society
- Vol. 18 (2) , 138-142
Open AccessA case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration
We present the case of an 88-year-old gentleman who presented to hospital septic with bilateral leg cellulitis, pulmonary oedema and hypotension. He had no history of heart disease but had had bilateral carpal tunnel releases. His condition deteriorated with refractory hypotension in spite of fluid filling, inotropic and vasopressor support. His echocardiogram showed an infiltrative cardiomyopathy with a speckled myocardium, severe concentric left and right ventricular increased wall thickness, diastolic dysfunction, biatrial dilatation and restrictive physiology in keeping with cardiac amyloidosis. He developed atrial fibrillation and worsening respiratory failure due to fluid overload and was intubated and ventilated but continued to decline and passed away. The degree of heart failure in the absence of ischaemia, the patient’s advanced age, echocardiographic findings and past history of carpal tunnel syndrome in a male are strongly indicative of a diagnosis of wild-type cardiac transthyretin amyloidosis. We discuss the key features and intensive care management of this disease.
- 1 January 2016
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 54 (1) , 71-80
Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization
Misfolding, polymerization, and defective secretion of functional alpha-1 antitrypsin underlies the predisposition to severe liver and lung disease in alpha-1 antitrypsin deficiency. We have identified a novel (Ala336Pro, Baghdad) deficiency variant and characterized it relative to the wild-type (M) and Glu342Lys (Z) alleles. The index case is a homozygous individual of consanguineous parentage, with levels of circulating alpha-1 antitrypsin in the moderate deficiency range, but is a biochemical phenotype that could not be classified by standard methods. The majority of the protein was present as functionally inactive polymer, and the remaining monomer was 37% active relative to the wild-type protein. These factors combined indicate an 85 to 95% functional deficiency, similar to that seen with ZZ homozygotes. Biochemical, biophysical, and computational studies further defined the molecular basis of this deficiency. These studies demonstrated that native Ala336Pro alpha-1 antitrypsin could populate the polymerogenic intermediate—and therefore polymerize—more readily than either wild-type alpha-1 antitrypsin or the Z variant. In contrast, folding was far less impaired in Ala336Pro alpha-1 antitrypsin than in the Z variant. The data are consistent with a disparate contribution by the “breach” region and “shutter” region of strand 5A to folding and polymerization mechanisms. Moreover, the findings demonstrate that, in these variants, folding efficiency does not correlate directly with the tendency to polymerize in vitro or in vivo. They therefore differentiate generalized misfolding from polymerization tendencies in missense variants of alpha-1 antitrypsin. Clinically, they further support the need to quantify loss-of-function in alpha-1 antitrypsin deficiency to individualize patient care.
- 1 January 2016
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 54 (1) , 71-80
Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization
Misfolding, polymerization, and defective secretion of functional alpha-1 antitrypsin underlies the predisposition to severe liver and lung disease in alpha-1 antitrypsin deficiency. We have identified a novel (Ala336Pro, Baghdad) deficiency variant and characterized it relative to the wild-type (M) and Glu342Lys (Z) alleles. The index case is a homozygous individual of consanguineous parentage, with levels of circulating alpha-1 antitrypsin in the moderate deficiency range, but is a biochemical phenotype that could not be classified by standard methods. The majority of the protein was present as functionally inactive polymer, and the remaining monomer was 37% active relative to the wild-type protein. These factors combined indicate an 85 to 95% functional deficiency, similar to that seen with ZZ homozygotes. Biochemical, biophysical, and computational studies further defined the molecular basis of this deficiency. These studies demonstrated that native Ala336Pro alpha-1 antitrypsin could populate the polymerogenic intermediate—and therefore polymerize—more readily than either wild-type alpha-1 antitrypsin or the Z variant. In contrast, folding was far less impaired in Ala336Pro alpha-1 antitrypsin than in the Z variant. The data are consistent with a disparate contribution by the “breach” region and “shutter” region of strand 5A to folding and polymerization mechanisms. Moreover, the findings demonstrate that, in these variants, folding efficiency does not correlate directly with the tendency to polymerize in vitro or in vivo. They therefore differentiate generalized misfolding from polymerization tendencies in missense variants of alpha-1 antitrypsin. Clinically, they further support the need to quantify loss-of-function in alpha-1 antitrypsin deficiency to individualize patient care.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , OA4487
LATE-BREAKING ABSTRACT: The heterogeneity of systemic inflammation in bronchiectasis
Rationale: Systemic inflammation in bronchiectasis is poorly studied in relation to disease aetiology and severity. Method: We assayed blood concentrations of 31 proteins from 90 patients with bronchiectasis (derivation cohort) and conducted PCA to examine relationships between these markers, disease aetiology and severity. Key results were validated in two separate cohorts of 97 and 79 patients. Results: There was significant heterogeneity in protein concentrations across the derivation cohort. Increasing severity of bronchiectasis (BSI) was associated with increasing fibrinogen concentration (rho=0.34, p=0.001 – validated in a second cohort), and higher fibrinogen was associated with worse lung function, Pseudomonas colonisation and impaired health status. There were generally similar patterns of inflammation in patients with idiopathic and post-infectious disease. Patients with primary immunodeficiency had exaggerated IL-17 responses, validated in a second cohort (immunodeficient 12.82 vs. idiopathic/post-infectious 4.95pg/ml, p=0.001), and thus IL-17 was able to discriminate primary immunodeficiency from other aetiologies (ROC AUC 0.769 (95%CI 0.661-0.877)). Conclusion: Bronchiectasis is associated with heterogeneity of systemic inflammatory proteins not adequately explained by differences in disease aetiology or disease severity. More severe disease is associated with an enhanced acute-phase response and we provide proof-of-principle that assay of systemic proteins may aid the diagnosis of specific conditions. Plasma fibrinogen was associated with bronchiectasis severity in two cohorts, Pseudomonas colonisation and health status, and offers potential as a useful biomarker.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , OA4487
LATE-BREAKING ABSTRACT: The heterogeneity of systemic inflammation in bronchiectasis
Rationale: Systemic inflammation in bronchiectasis is poorly studied in relation to disease aetiology and severity. Method: We assayed blood concentrations of 31 proteins from 90 patients with bronchiectasis (derivation cohort) and conducted PCA to examine relationships between these markers, disease aetiology and severity. Key results were validated in two separate cohorts of 97 and 79 patients. Results: There was significant heterogeneity in protein concentrations across the derivation cohort. Increasing severity of bronchiectasis (BSI) was associated with increasing fibrinogen concentration (rho=0.34, p=0.001 – validated in a second cohort), and higher fibrinogen was associated with worse lung function, Pseudomonas colonisation and impaired health status. There were generally similar patterns of inflammation in patients with idiopathic and post-infectious disease. Patients with primary immunodeficiency had exaggerated IL-17 responses, validated in a second cohort (immunodeficient 12.82 vs. idiopathic/post-infectious 4.95pg/ml, p=0.001), and thus IL-17 was able to discriminate primary immunodeficiency from other aetiologies (ROC AUC 0.769 (95%CI 0.661-0.877)). Conclusion: Bronchiectasis is associated with heterogeneity of systemic inflammatory proteins not adequately explained by differences in disease aetiology or disease severity. More severe disease is associated with an enhanced acute-phase response and we provide proof-of-principle that assay of systemic proteins may aid the diagnosis of specific conditions. Plasma fibrinogen was associated with bronchiectasis severity in two cohorts, Pseudomonas colonisation and health status, and offers potential as a useful biomarker.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , OA468
Determinants and assessment of excess cardiovascular risk in bronchiectasis
Background: Obstructive lung diseases carry a significant burden of cardiovascular comorbidity. This comorbidity is well studied in COPD but few studies to date have examined it within the context of bronchiectasis. Introduction: Bronchiectasis patients have greater cardiovascular risk compared to controls but the determinants are unclear. We aimed to assess cardiovascular risk in patients with bronchiectasis using serum cardiac biomarkers and aortic stiffness and assess whether measured risk was accurately calculated by the QRISK2 score. We also sought to identify factors significantly associated with cardiovascular risk in bronchiectasis. Method: We measured aortic stiffness (pulsewave velocity), cardiac and inflammatory biomarkers in 101 patients with stable (non cystic fibrosis) bronchiectasis. We compared measured cardiovascular risk to risk calculated using the QRISK 2 score, and identified features associated with higher risk. Results: The composite bronchiectasis severity index (BSI) correlated with measured cardiovascular risk assessments. Aortic stiffness was significantly higher in frequent (≥3 /year) exacerbators (10.5 vs 9.2 m/s, p=0.01). The QRISK2 score under-estimated cardiovascular risk in patients with bronchiectasis (median relative risk change= 1.29). Risk was particularly underestimated in frequent exacerbators and males. Conclusion: We confirm excess cardiovascular risk in bronchiectasis. This excess risk is associated with exacerbation frequency and impaired lung function. The QRISK2 calculator underestimates risk in bronchiectasis – especially in men and frequent exacerbators. Risk assessment in bronchiectasis should be individualised and not rely on standardised calculators.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , OA468
Determinants and assessment of excess cardiovascular risk in bronchiectasis
Background: Obstructive lung diseases carry a significant burden of cardiovascular comorbidity. This comorbidity is well studied in COPD but few studies to date have examined it within the context of bronchiectasis. Introduction: Bronchiectasis patients have greater cardiovascular risk compared to controls but the determinants are unclear. We aimed to assess cardiovascular risk in patients with bronchiectasis using serum cardiac biomarkers and aortic stiffness and assess whether measured risk was accurately calculated by the QRISK2 score. We also sought to identify factors significantly associated with cardiovascular risk in bronchiectasis. Method: We measured aortic stiffness (pulsewave velocity), cardiac and inflammatory biomarkers in 101 patients with stable (non cystic fibrosis) bronchiectasis. We compared measured cardiovascular risk to risk calculated using the QRISK 2 score, and identified features associated with higher risk. Results: The composite bronchiectasis severity index (BSI) correlated with measured cardiovascular risk assessments. Aortic stiffness was significantly higher in frequent (≥3 /year) exacerbators (10.5 vs 9.2 m/s, p=0.01). The QRISK2 score under-estimated cardiovascular risk in patients with bronchiectasis (median relative risk change= 1.29). Risk was particularly underestimated in frequent exacerbators and males. Conclusion: We confirm excess cardiovascular risk in bronchiectasis. This excess risk is associated with exacerbation frequency and impaired lung function. The QRISK2 calculator underestimates risk in bronchiectasis – especially in men and frequent exacerbators. Risk assessment in bronchiectasis should be individualised and not rely on standardised calculators.
- Open Access
- 27 July 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (7) , e0134004
The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit
There is controversy regarding the significance of radiological consolidation in the context of COPD exacerbation (eCOPD). While some studies into eCOPD exclude these cases, consolidation is a common feature of eCOPD admissions in real practice. This study aims to address the question of whether consolidation in eCOPD is a distinct clinical phenotype with implications for management decisions and outcomes. The European COPD Audit was carried out in 384 hospitals from 13 European countries between 2010 and 2011 to analyze guideline adherence in eCOPD. In this analysis, admissions were split according to the presence or not of consolidation on the admission chest radiograph. Groups were compared in terms of clinical and epidemiological features, existing treatment, clinical care utilized and mortality. 14,111 cases were included comprising 2,714 (19.2%) with consolidation and 11,397 (80.8%) without. The risk of radiographic consolidation increased with age, female gender, cardiovascular diseases, having had two or more admissions in the previous year, and sputum color change. Previous treatment with inhaled steroids was not associated. Patients with radiographic consolidation were significantly more likely to receive antibiotics, oxygen and non-invasive ventilation during the admission and had a lower survival from admission to 90-day follow-up. Patients admitted for COPD exacerbation who have radiological consolidation have a more severe illness course, are treated more intensively by clinicians and have a poorer prognosis. We recommend that these patients be considered a distinct subset in COPD exacerbation.
- 27 July 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (7) , e0134004
Open AccessThe Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit
There is controversy regarding the significance of radiological consolidation in the context of COPD exacerbation (eCOPD). While some studies into eCOPD exclude these cases, consolidation is a common feature of eCOPD admissions in real practice. This study aims to address the question of whether consolidation in eCOPD is a distinct clinical phenotype with implications for management decisions and outcomes. The European COPD Audit was carried out in 384 hospitals from 13 European countries between 2010 and 2011 to analyze guideline adherence in eCOPD. In this analysis, admissions were split according to the presence or not of consolidation on the admission chest radiograph. Groups were compared in terms of clinical and epidemiological features, existing treatment, clinical care utilized and mortality. 14,111 cases were included comprising 2,714 (19.2%) with consolidation and 11,397 (80.8%) without. The risk of radiographic consolidation increased with age, female gender, cardiovascular diseases, having had two or more admissions in the previous year, and sputum color change. Previous treatment with inhaled steroids was not associated. Patients with radiographic consolidation were significantly more likely to receive antibiotics, oxygen and non-invasive ventilation during the admission and had a lower survival from admission to 90-day follow-up. Patients admitted for COPD exacerbation who have radiological consolidation have a more severe illness course, are treated more intensively by clinicians and have a poorer prognosis. We recommend that these patients be considered a distinct subset in COPD exacerbation.
- Open Access
- 1 January 2015
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 6 (9) , 437-439
Takotsubo Cardiomyopathy Post Induction of Anesthesia
We report the case of a 67-year-old female patient who underwent radiofrequency ablation of a renal cell carcinoma, and developed dynamic ST elevation immediately following induction of anesthesia. She was transferred to the cardiac catheterization laboratory where she underwent a coronary angiogram. This showed no obstruction of the coronary arteries, but an echocardiogram demonstrated an ejection fraction of 20% with a picture suggestive of Takotsubo cardiomyopathy. The patient later developed pulmonary edema requiring continuous positive pressure ventilation (CPAP), inotropes and vasopressors. She made a good recovery by the third day following induction, with resolution of her elevated ST segments, troponin and impaired ejection fraction. J Med Cases. 2015;6(9):437-439 doi: http://dx.doi.org/10.14740/jmc2280w
- 1 January 2015
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 6 (9) , 437-439
Open AccessTakotsubo Cardiomyopathy Post Induction of Anesthesia
We report the case of a 67-year-old female patient who underwent radiofrequency ablation of a renal cell carcinoma, and developed dynamic ST elevation immediately following induction of anesthesia. She was transferred to the cardiac catheterization laboratory where she underwent a coronary angiogram. This showed no obstruction of the coronary arteries, but an echocardiogram demonstrated an ejection fraction of 20% with a picture suggestive of Takotsubo cardiomyopathy. The patient later developed pulmonary edema requiring continuous positive pressure ventilation (CPAP), inotropes and vasopressors. She made a good recovery by the third day following induction, with resolution of her elevated ST segments, troponin and impaired ejection fraction. J Med Cases. 2015;6(9):437-439 doi: http://dx.doi.org/10.14740/jmc2280w
- Open Access
P59 Utility Of Fib4 Score And Liver Disease In Alpha-1 Antitrypsin Deficiency (a1atd)
Introduction A1ATD is an autosomal co-dominant condition where homozygosity for the Z-allele results, classically, in emphysematous lung involvement, and liver fibrosis dependant on polymerisation rate of aberrant protein.1 The FIB4 score non-invasively estimates risk of liver fibrosis,2 but has not previously been investigated in A1ATD. We completed preliminary assessment of the utility of FIB4 in our A1ATD cohort. Whilst the standard of care in A1ATD should be joint respiratory-hepatology services, not all patients are able to access this. A simple tool to guide referral to hepatology services could therefore be clinically useful to the respiratory community. Methods We report data from 30 PiZZ patients with ultrasound (USS) characterisation of liver disease. An abnormal USS was considered as any abnormality other than cysts, thus including features of cirrhosis and fatty infiltration. FIB4 was calculated as [Age (years)xAST(U/l)]/[Platelets (109)xALT(U/l)]. The most recent lung physiology was recorded as FEV1 (%predicted), diffusion coefficient (KCO,%predicted) and residual volume (RV,%predicted). Body mass index (BMI) was calculated. Results The 30 patients had a mean age of 54 ± 12.4 years, 14 were male. Lung function showed mean FEV1 1.85 ± 1.12 L (61.3 ± 30.9%), KCO 1.05 ± 0.40 mmol/min/kPa/L (66.4 ± 22.2%) and RV 3.58 ± 1.36 L (171.8 ± 50.4%). The mean FIB4 was 1.76 ± 1.36. Eight (26.7%) patients had liver disease on USS. FIB4 cut-off values of 1.45 and 3.25 were utilised, as they are widely validated.3 Of patients >3.25, 100% had abnormal scans (PPV 100%), and of patients Conclusions The FIB4 score, calculated from routine laboratory variables and age, may be useful to rule in and out significant liver involvement in A1ATD with reasonable sensitivity and specificity. Further work is required for validation against biopsy, the gold-standard assessment. We confirm a previously noted lack of association between liver disease and emphysema severity,4 and highlight the association between higher BMI and higher fibrosis risk in A1ATD. ROC of the FIB4 index for detection of abnormal USS
Open AccessP59 Utility Of Fib4 Score And Liver Disease In Alpha-1 Antitrypsin Deficiency (a1atd)
Introduction A1ATD is an autosomal co-dominant condition where homozygosity for the Z-allele results, classically, in emphysematous lung involvement, and liver fibrosis dependant on polymerisation rate of aberrant protein.1 The FIB4 score non-invasively estimates risk of liver fibrosis,2 but has not previously been investigated in A1ATD. We completed preliminary assessment of the utility of FIB4 in our A1ATD cohort. Whilst the standard of care in A1ATD should be joint respiratory-hepatology services, not all patients are able to access this. A simple tool to guide referral to hepatology services could therefore be clinically useful to the respiratory community. Methods We report data from 30 PiZZ patients with ultrasound (USS) characterisation of liver disease. An abnormal USS was considered as any abnormality other than cysts, thus including features of cirrhosis and fatty infiltration. FIB4 was calculated as [Age (years)xAST(U/l)]/[Platelets (109)xALT(U/l)]. The most recent lung physiology was recorded as FEV1 (%predicted), diffusion coefficient (KCO,%predicted) and residual volume (RV,%predicted). Body mass index (BMI) was calculated. Results The 30 patients had a mean age of 54 ± 12.4 years, 14 were male. Lung function showed mean FEV1 1.85 ± 1.12 L (61.3 ± 30.9%), KCO 1.05 ± 0.40 mmol/min/kPa/L (66.4 ± 22.2%) and RV 3.58 ± 1.36 L (171.8 ± 50.4%). The mean FIB4 was 1.76 ± 1.36. Eight (26.7%) patients had liver disease on USS. FIB4 cut-off values of 1.45 and 3.25 were utilised, as they are widely validated.3 Of patients >3.25, 100% had abnormal scans (PPV 100%), and of patients Conclusions The FIB4 score, calculated from routine laboratory variables and age, may be useful to rule in and out significant liver involvement in A1ATD with reasonable sensitivity and specificity. Further work is required for validation against biopsy, the gold-standard assessment. We confirm a previously noted lack of association between liver disease and emphysema severity,4 and highlight the association between higher BMI and higher fibrosis risk in A1ATD. ROC of the FIB4 index for detection of abnormal USS
- 30 April 2014
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 43 (5) , 1217-1219
How to assess the severity of bronchiectasis
- 30 April 2014
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 43 (5) , 1217-1219
How to assess the severity of bronchiectasis